Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design

Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Gavin Dabrera, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2023.09.28.23296290

Article Information

doi 
https://doi.org/10.1101/2023.09.28.23296290
History 
  • September 29, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Freja Cordelia Møller Kirsebom, PhD1,
  2. Nick Andrews, PhD1,2,
  3. Julia Stowe, PhD1,
  4. Gavin Dabrera1,
  5. Mary Ramsay, MBBS1,2 and
  6. Jamie Lopez Bernal, PhD*,1,2,3
  1. 1UK Health Security Agency, London, United Kingdom
  2. 2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
  3. 3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, United Kingdom
  1. ↵*Corresponding author: Jamie.LopezBernal2{at}ukhsa.gov.uk
Back to top
Posted September 29, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design
Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Gavin Dabrera, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2023.09.28.23296290; doi: https://doi.org/10.1101/2023.09.28.23296290
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area